VetDC Receives FDA Conditional Approval of TANOVEA™-CA1, the First New Animal Drug for Treating Lymphoma in Dogs

FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., a veterinary cancer therapeutics company, today announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) has granted a conditional approval of Tanovea™-CA1 (rabacfosadine for injection) for the treatment of lymphoma in … Keep Reading

VetDC achieves key regulatory milestone, nears FDA approval of TANOVEA™-CA1 for Canine Lymphoma

FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., a veterinary cancer therapeutics company, today announced that the Company has received three major technical section complete letters for Tanovea™-CA1 (rabacfosadine) from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA-CVM). Upon approval, … Keep Reading